J
James J. Powell
Researcher at University of Edinburgh
Publications - 27
Citations - 970
James J. Powell is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Transplantation & Liver transplantation. The author has an hindex of 15, co-authored 26 publications receiving 798 citations. Previous affiliations of James J. Powell include St Thomas' Hospital & NHS Lothian.
Papers
More filters
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer.
TL;DR: The possession of a genotype resulting in increased IL-1b production was associated with shortened survival and increased serum CRP level, which may reflect the role of IL- 1b in inducing an acute phase protein response and cachexia in cancer or may be related to changes in tumour phenotye.
Journal ArticleDOI
Activation of nuclear factor kappa b in crohn's disease
TL;DR: Increased activation in the submucosa of non-inflamed Crohn's disease bowel provides further evidence of early immunological activation in macroscopically and microscopically uninvolved areas and an underlying abnormal immune system in Crohn't disease.
Journal ArticleDOI
Evidence against a role for polymorphisms at tumor necrosis factor, interleukin-1 and interleukin—1 receptor antagonist gene loci in the regulation of disease severity in acute pancreatitis
TL;DR: Observations suggest that genetic factors are not important in determining TNF-alpha secretion in patients with acute pancreatitis, however, a predetermined imbalance between IL-1beta and its antagonistIL-1RA would appear to exist in Patients with severe acute Pancreatitis.
Journal ArticleDOI
Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma.
William A. Cambridge,Cameron J Fairfield,James J. Powell,Ewen M Harrison,Kjetil Søreide,Stephen J. Wigmore,Rachel V. Guest +6 more
TL;DR: In unresectable pCC, NCR-OLT confers long-term survival in highly selected patients able to complete neoadjuvant chemoradiation followed by transplantation, and PSC patients appear to have the most favorable outcomes.